Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
06/2010
06/08/2010CA2433453C Triazolo[4,5-d]pyrimidine derivatives and their use as purinergic receptor antagonists
06/08/2010CA2433039C Agent for therapeutic and prophylactic treatment of neuropathic pain
06/08/2010CA2432388C Aminoacetonitriles to control endoparasitic pests
06/08/2010CA2431983C Novel 1,2-diphenylazetidinones, processes for their preparation, medicaments comprising these compounds and their use for treating impaired lipid metabolism
06/08/2010CA2429168C Method for restoring a damaged or degenerated intervertebral disc
06/08/2010CA2416442C Substituted 5-alkynyl pyrimidines having neurotrophic activity
06/08/2010CA2403674C The use of t3 for treating congestive heart failure
06/08/2010CA2397670C .beta.-turn peptidomimetic cyclic compounds
06/08/2010CA2389300C 4-phenyl-substituted tetrahydroisoquinolines and use thereof to block reuptake of norepinephrine, dopamine and serotonin
06/08/2010CA2388063C Cytotoxic agents comprising taxanes and their therapeutic use
06/08/2010CA2386547C Orally disintegrating composition comprising mirtazapine
06/08/2010CA2383233C Surface modified particulate compositions of biologically active substances
06/08/2010CA2379210C Composition for enteral nutrition containing fibre
06/08/2010CA2370019C Transdermal therapeutic system with neutralized acrylic pressure-sensitive adhesives
06/08/2010CA2369300C Water-soluble compositions of bioactive lipophilic compounds
06/08/2010CA2368135C Xylo-lna analogues
06/08/2010CA2360590C Solution-based transdermal drug delivery system
06/08/2010CA2333935C Anti-germ attachment - composition
06/08/2010CA2283684C Down-regulation of gene expression by colorectal administration of synthetic oligonucleotides
06/08/2010CA2275060C Novel triglyceride and composition comprising the same
06/08/2010CA2266342C Packaging cell lines for use in facilitating the development of high-capacity adenoviral vectors
06/08/2010CA2210956C Method for preparing a recombinant adenovirus genome
06/08/2010CA2144475C Polyamide-oligonucleotide derivatives, their preparation and use
06/08/2010CA1341606C Activation of nf-kb precursor
06/05/2010CA2645982A1 Use of ave5026 for minimizing the incidence of bleedings during an antithrombotic treatment
06/03/2010WO2010063011A2 Methods for the treatment of infections and tumors
06/03/2010WO2010062996A2 Ribavirin composition
06/03/2010WO2010062966A2 Methods for inducing mixed chimerism
06/03/2010WO2010062961A1 Compositions and methods for treating hoof diseases
06/03/2010WO2010062959A1 5-ht4 receptor agonists for treating irritable bowel syndrome and colonic hypersensitivity
06/03/2010WO2010062930A1 Compositions and methods for hyperhidrosis
06/03/2010WO2010062927A2 Novel substituted octahydrocyclopenta(c)pyrrol-4-amines as calcium channel blockers
06/03/2010WO2010062900A2 A new family of pain producing substances and methods to produce novel analgesic drugs
06/03/2010WO2010062861A2 Bile acid recycling inhibitors for treatment of obesity and diabetes
06/03/2010WO2010062848A1 Substituted pyrazole compounds
06/03/2010WO2010062846A1 Synthesis of stable organogold compounds and methods of use thereof
06/03/2010WO2010062835A1 Antioxidant compositions for soft oral tissue and methods of formulation and use there
06/03/2010WO2010062829A1 Tryptophan hydroxylase inhibitors for treating osteoporosis
06/03/2010WO2010062824A2 Enhanced bioactive formulations of resveratrol
06/03/2010WO2010062821A1 Anti-viral compounds, compositions, and methods of use
06/03/2010WO2010062817A1 RNA INTERFERENCE MEDIATED INHIBITION OF EPITHELIAL SODIUM CHANNEL (ENaC) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
06/03/2010WO2010062742A2 Methods for freparation and use of marrow infiltrating lymphocytes (mils)
06/03/2010WO2010062692A1 Combination of morphinan compounds and antidepressant for the treatment of pseudobulbar affect, neurological diseases, intractable and chronic pain and brain injury
06/03/2010WO2010062690A1 Combination of morphinan compounds and antidepressant for the treatment of pseudobulbar affect, neurological diseases, intractable and chronic pain and brain injury
06/03/2010WO2010062688A2 Dosage form for insertion into the mouth
06/03/2010WO2010062686A2 Imidazol-4-one and imidazole-4-thione compounds
06/03/2010WO2010062681A2 Luteolin and diosmin/diosmetin as novel stat3 inhibitors for treating autism
06/03/2010WO2010062656A2 Deuterated 2-propylpentanoic acid compounds
06/03/2010WO2010062640A1 Methods for treating idiopathic pulmonary fibrosis and associated complications
06/03/2010WO2010062581A2 A botanical composition for enhanced skin repair and uses thereof
06/03/2010WO2010062578A1 Pyrazolylaminopyridines as inhibitors of fak
06/03/2010WO2010062571A1 Mtor kinase inhibitors for oncology indications and diseases associated with the mtor/p13k/akt pathway
06/03/2010WO2010062565A1 Muscarinic agonists
06/03/2010WO2010062562A1 Synthesis and use of cationic steroids for anti-inflammatory drug therapy
06/03/2010WO2010062559A1 Substituted pyrazoloquinolines and derivatives thereof
06/03/2010WO2010062524A1 Extended release oral acetaminophen/tramadol dosage form
06/03/2010WO2010062523A2 Prostaglandin and prostamide drug delivery systems and intraocular therapeutic uses thereof
06/03/2010WO2010062507A1 Disubstituted phthalazine hedgehog pathway antagonists
06/03/2010WO2010062506A2 Decahydro-1h-indenoquinolinone and decahydro-3h-cyclopentaphenanthridinone cyp17 inhibitors
06/03/2010WO2010062415A1 Nitrooxy cycloalkane derivatives
06/03/2010WO2010062381A1 Organelle-specific drug delivery
06/03/2010WO2010062372A2 Methods for modulating nf-kb using gibberellins
06/03/2010WO2010062366A1 Compositions and methods of treating endothelial disorders
06/03/2010WO2010062323A2 Compositions of a 5-ht2a serotonin receptor modulator useful for the treatment of disorders related thereto
06/03/2010WO2010062322A2 Modulation of the immune response
06/03/2010WO2010062308A1 Modulators of aldehyde dehydrogenase and methods of use thereof
06/03/2010WO2010062265A1 Therapeutic macrolide compounds and their use
06/03/2010WO2010062261A1 System and method for preparing a controlled releas preparation
06/03/2010WO2010062260A1 Virus and target cell interaction inhibition
06/03/2010WO2010062245A1 Spirocyclobutyl piperidine derivatives
06/03/2010WO2010062221A1 Substituted 2-(5-hydroxy-2-methyl-1n-indole-3-il) acetic acids and ethers thereof and the use of same to treat viral diseases
06/03/2010WO2010062206A1 Choline salts of succinic acid for the treatment of depression, anxiety, schizophrenia, sleep disorder, and epilepsy
06/03/2010WO2010062205A2 Indication of use of erdosteine as antidote in a large number of intoxications, especially in heavy metals like lead or mercury, and paracetamol
06/03/2010WO2010062197A1 Dairy product and process
06/03/2010WO2010062194A1 Animal treatment formulation and methods of use
06/03/2010WO2010062190A1 Improvements in bolus devices for the delivery of active agents to animals
06/03/2010WO2010062153A1 Pharmaceutical compositions containing melatonin for treatment of internal tissue and organ burns caused by corrosive substances
06/03/2010WO2010062144A2 Ethacrynic acid-containing composition and method for prevention and treatment of transglutaminase-related diseases
06/03/2010WO2010062136A2 Composition for mitochondrial activation
06/03/2010WO2010061971A1 Pyridine-3-carboxyamide derivative
06/03/2010WO2010061931A1 Cyclobutyl purine derivative, angiogenesis promoting agent, lumenization promoting agent, neurocyte growth promoting agent, and drug
06/03/2010WO2010061921A1 Method for stabilizing l-ascorbic acid, liquid extraction preparation, solid extract, and semi-fluid extract
06/03/2010WO2010061908A1 1-(2h)-isoquinolone derivative
06/03/2010WO2010061907A1 Anti-cancer agent
06/03/2010WO2010061903A1 Pyrimidine derivative and pyridine derivative both having pi3k inhibitory activity
06/03/2010WO2010061881A1 Oligoribonucleotide or peptide nucleic acid capable of inhibiting activity of hepatitis c virus
06/03/2010WO2010061880A1 Vesicle preparation
06/03/2010WO2010061877A1 Mineral absorption improver, and method for improving absorption of minerals
06/03/2010WO2010061862A1 Antitumor agent containing thalidomide derivative as active ingredient
06/03/2010WO2010061846A1 Orally rapidly disintegrating tablet, and process for producing same
06/03/2010WO2010061574A1 Sleep-improving agent, sedative agent, and use thereof
06/03/2010WO2010061497A1 Anti-influenza virus agent
06/03/2010WO2010061412A1 New composition for bakery products
06/03/2010WO2010061407A1 Genetic variants useful for risk assessment of thyroid cancer
06/03/2010WO2010061396A1 Methods for detecting an increased susceptibility to cancer
06/03/2010WO2010061360A1 Antitumor combinations containing antibodies recognizing specifically cd38 and cylophosphamide
06/03/2010WO2010061359A1 Antitumor combinations containing antibodies recognizing specifically cd38 and cytarabine
06/03/2010WO2010061358A1 Antitumor combinations containing antibodies recognizing specifically cd38 and vincristine
06/03/2010WO2010061357A1 Antitumor combinations containing antibodies recognizing specifically cd38 and melphalan
06/03/2010WO2010061329A1 3-aminocyclopentanecarboxamides as chemokine receptor modulators
1 ... 2237 2238 2239 2240 2241 2242 2243 2244 2245 2246 2247 2248 2249 2250 2251 2252 2253 2254 2255 2256 2257 ... 7860